United Therapeutics Acquires Miromatrix Medical to Strengthen its Organ Manufacturing Portfolio Including Ex-Vivo Lung Perfusion and 3D Bioprinting

Published: October 2023


On 30 October 2023, United Therapeutics announced the acquisition of Miromatrix Medical, a life sciences company specializing in the development of bioengineered human cell-based organs. 

This strategic acquisition aims to strengthen United Therapeutics' existing portfolio of organ manufacturing programs, including ex-vivo lung perfusion, xenotransplantation, 3-D bioprinting, and regenerative medicine approaches, in order to generate an abundant supply of transplantable organs that the body can tolerate. Under the terms of the agreement, United Therapeutics plans to purchase all the outstanding shares of Miromatrix. The proposed purchase price is $3.25 per share in cash upon closing, totaling around $91 million. Further, there will be an extra $1.75 per share in cash to be paid upon the successful attainment of a clinical development milestone associated with Miromatrix's mirokidney™, a fully implantable manufactured kidney product, expected to be achieved by December 31, 2025.

According to Roots Analysis, the 4D Bioprinting Market is estimated to be worth $21 million in 2023 and is expected to grow at a CAGR of 34% during the forecast period.

For detailed insights about this domain, check out our report on 4D Bioprinting Market or email sales@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry